How much does Palbociclib cost after reimbursement?

Palbociclib (Palbociclib) is used to treat estrogen receptor-positive andHER2-negative breast cancer. After the original drug palbociclib was launched in China, it has entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Administration, but it is only reimbursable for patients with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer. Patients who do not meet the conditions can only Purchase at your own expense. Different regions have different reimbursement ratios, and the price after reimbursement may be different. According to the medical insurance payment standards of the Medical Insurance Bureau, the price after reimbursement for 75mg/tablet is 137.7 yuan; the price after reimbursement for 100mg/tablet is 171.63 yuan; and the price after reimbursement for 125mg/tablet is 203.6 yuan.